Thus, to us, the key potential positive events that could lead to a rerating in PHRM.CN shares include publication of the Phase 2 trial data evaluating ketamine in LID-PD in 2H22, which could increase investor confidence in the program, an update on the KETABET program, which we believe could generate annual revenues of $1B-plus, if approved, and an update on the status of the ANDA filing, which if approved could provide a source of cash over the long-term to fund future drug development. Ahead of these potential positive events, we reiterate our Buy rating and $3.84 price target on PHRM.CN shares. HC Wainwright
H.C. Wainwright & Co., LLC managed or co-managed a public offering of securities for PharmaTher Holdings Ltd. during the past 12 months. Please see report for full disclosure and disclaimer details.
